Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 383 full-time employees. The company went IPO on 2019-05-31. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The firm is also engaged in the transfer of intellectual property. The firm mainly conducts its business in the domestic market.
02181.HK stock price ended at $0.51 on Jueves, after rising 0.00%
On the latest trading day Feb 12, 2026, the stock price of 02181.HK rose by 0.00%, climbing from $0.51 to $0.51. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.51 and a high of $0.51. Alongside this price increase, trading volume also rose by 18.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, -- shares were traded, amounting to a market value of approximately $2.1B.
Señales Técnicas de 02181.HK
Resumen de Señales Técnicas
Señales de compra 2
Señales Neutras 1
Señales de venta 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
02181.HK actualmente presenta 2 señales de compra y 4 señales de venta. La acción ha estado en una tendencia alcista desde 12:00 AM, con un cambio total en el precio de -- durante este período. En general, los indicadores técnicos apuntan a una perspectiva Sell para el mediano plazo.
Señales alcistas/bajistas para 02181.HK
Analizamos indicadores clave como medias móviles, RSI, MACD y volumen de negociación para generar señales alcistas y bajistas para 02181.HK. Estas perspectivas te ayudan a tomar decisiones de inversión más informadas.